Strides Pharma Science Limited, in its Board Meeting held on May 18, 2026, approved the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026. The company reported a strong performance for the fourth quarter, with consolidated revenue from operations rising to ₹1,323.47 crore from ₹1,190.39 crore in the corresponding quarter of the previous year. Consolidated net profit for the quarter ended March 31, 2026, reached ₹129.28 crore, reflecting a 51% increase year-on-year from ₹85.62 crore. The company’s performance highlights significant growth driven by non-US markets, which helped offset soft demand in the US region during the quarter.

*Note: Comparative data for the immediate preceding quarter (Q3 FY26) is not explicitly detailed in the source for the final amount analysis; the table above focuses on YoY analysis as provided.

Strides Pharma Science Limited is a global pharmaceutical company headquartered in Bengaluru, India, specializing in the development, manufacture, and commercialization of a wide range of high-quality, affordable generic medicines. The company’s diverse portfolio spans complex generics, including tablets, hard capsules, liquids, and topical products, serving regulated and emerging markets across over 100 countries. Known for its inorganic growth strategy, Strides focuses on IP-led niche finished dosage formulations and is among the world’s largest manufacturers of soft gelatin capsules. Recent updates include the approved reconstitution of its Board of Directors and senior management, effective June 1, 2026, to strengthen its succession planning framework. Furthermore, in early 2026, the company successfully closed a USFDA inspection for its Chestnut Ridge facility, bolstering its US business prospects. As of mid-2025, Quant Mutual Fund was identified as a notable public shareholder, and the company’s promoter group, led by Pronomz Ventures LLP, maintains a substantial stake.